112 related articles for article (PubMed ID: 35183932)
1. Inhibition of factor Xa activity, platelet aggregation, and experimentally induced thrombosis by Sparstolonin B.
Kim N; Jeon C; Kim C; Ryu SH; Lee W; Bae JS
Phytomedicine; 2022 May; 99():153987. PubMed ID: 35183932
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet Aggregation Properties of Cirsilineol: A Novel Inhibitor of Blood Coagulation Factor Xa.
Kim GO; Heo JB; Park DH; Song GY; Bae JS
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111345
[TBL] [Abstract][Full Text] [Related]
3. Novel factor Xa inhibitor, maslinic acid, with antiplatelet aggregation activity.
Kim KM; Kim J; Baek MC; Bae JS
J Cell Physiol; 2020 Dec; 235(12):9445-9456. PubMed ID: 32356316
[TBL] [Abstract][Full Text] [Related]
4. Novel direct factor Xa inhibitory compounds from Tenebrio molitor with anti-platelet aggregation activity.
Lee W; Kim MA; Park I; Hwang JS; Na M; Bae JS
Food Chem Toxicol; 2017 Nov; 109(Pt 1):19-27. PubMed ID: 28844963
[TBL] [Abstract][Full Text] [Related]
5. Anti-factor Xa activities of zingerone with anti-platelet aggregation activity.
Lee W; Ku SK; Kim MA; Bae JS
Food Chem Toxicol; 2017 Jul; 105():186-193. PubMed ID: 28414123
[TBL] [Abstract][Full Text] [Related]
6. Sparstolonin B suppresses lipopolysaccharide-induced inflammation in human umbilical vein endothelial cells.
Liang Q; Yu F; Cui X; Duan J; Wu Q; Nagarkatti P; Fan D
Arch Pharm Res; 2013 Jul; 36(7):890-6. PubMed ID: 23604718
[TBL] [Abstract][Full Text] [Related]
7. Anti-Inflammatory Effect of Sparstolonin B through Inhibiting Expression of NF-κB and STAT-1.
Kim N; Kim C; Ryu SH; Kim GO; Bae JS
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142124
[TBL] [Abstract][Full Text] [Related]
8. Sparstolonin B inhibits lipopolysaccharide-induced inflammation in 3T3-L1 adipocytes.
Wang M; Xiu L; Diao J; Wei L; Sun J
Eur J Pharmacol; 2015 Dec; 769():79-85. PubMed ID: 26522926
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p38 and ERK1/2 pathways by Sparstolonin B suppresses inflammation-induced melanoma metastasis.
Tang YM; Cao QY; Guo XY; Dong SH; Duan JA; Wu QN; Liang QL
Biomed Pharmacother; 2018 Feb; 98():382-389. PubMed ID: 29276966
[TBL] [Abstract][Full Text] [Related]
10. Sparstolonin B inhibits pro-angiogenic functions and blocks cell cycle progression in endothelial cells.
Bateman HR; Liang Q; Fan D; Rodriguez V; Lessner SM
PLoS One; 2013; 8(8):e70500. PubMed ID: 23940584
[TBL] [Abstract][Full Text] [Related]
11. Neferine exerts its antithrombotic effect by inhibiting platelet aggregation and promoting dissociation of platelet aggregates.
Zhou YJ; Xiang JZ; Yuan H; Liu H; Tang Q; Hao HZ; Yin Z; Wang J; Ming ZY
Thromb Res; 2013 Aug; 132(2):202-10. PubMed ID: 23773522
[TBL] [Abstract][Full Text] [Related]
12. A novel role of andrographolide, an NF-kappa B inhibitor, on inhibition of platelet activation: the pivotal mechanisms of endothelial nitric oxide synthase/cyclic GMP.
Lu WJ; Lee JJ; Chou DS; Jayakumar T; Fong TH; Hsiao G; Sheu JR
J Mol Med (Berl); 2011 Dec; 89(12):1261-73. PubMed ID: 21822619
[TBL] [Abstract][Full Text] [Related]
13. Sparstolonin B, a novel plant derived compound, arrests cell cycle and induces apoptosis in N-myc amplified and N-myc nonamplified neuroblastoma cells.
Kumar A; Fan D; Dipette DJ; Singh US
PLoS One; 2014; 9(5):e96343. PubMed ID: 24788776
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of Sparstolonin B, a selective TLR2 and TLR4 antagonist, on mouse endotoxin shock.
Liang Q; Dong S; Lei L; Liu J; Zhang J; Li J; Duan J; Fan D
Cytokine; 2015 Oct; 75(2):302-9. PubMed ID: 25573805
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of novel factor Xa inhibitors from Oxya chinensis sinuosa with anti-platelet aggregation activity.
Lee W; Lee H; Kim MA; Choi J; Kim KM; Hwang JS; Na M; Bae JS
Sci Rep; 2017 Aug; 7(1):7934. PubMed ID: 28801633
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban.
Qiu X; Wang W; Zhao Z; Sun S; Tang L
Eur J Pharmacol; 2018 Oct; 836():50-56. PubMed ID: 30125563
[TBL] [Abstract][Full Text] [Related]
18. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
Furugohri T; Isobe K; Honda Y; Kamisato-Matsumoto C; Sugiyama N; Nagahara T; Morishima Y; Shibano T
J Thromb Haemost; 2008 Sep; 6(9):1542-9. PubMed ID: 18624979
[TBL] [Abstract][Full Text] [Related]
19. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
20. A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from Agkistrodon acutus Venom Hydrolysates.
Chen M; Ye X; Ming X; Chen Y; Wang Y; Su X; Su W; Kong Y
Sci Rep; 2015 Jun; 5():10846. PubMed ID: 26035670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
